Announcement on Receiving Notice of Approval for Clinical Trial of SQ-23101 Injection

Shenyang Xingqi Pharmaceutical Co., Ltd.·July 13, 2026·2 pages

✨ AI Summary

Shenyang Xingqi Pharmaceutical Co., Ltd. announced it received approval from China's NMPA for the clinical trial of SQ-23101 Injection, a novel biologic for treating thyroid eye disease. The company has completed preclinical studies demonstrating good safety and value. The approval allows the company to proceed with clinical research, a crucial step towards potential market launch.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· gemini_document

Securities Code: 300573

Securities Abbreviation: Xingqi Pharmaceutical

Announcement No.: 2026-037

Shenyang Xingqi Pharmaceutical Co., Ltd.

Announcement on Receiving Notice of Approval for Clinical Trial of SQ-23101 Injection

The Company and all members of the Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed, and that there are no false records, misleading statements, or major omissions.

Recently, Shenyang Xingqi Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") received the "Notice of Approval for Drug Clinical Trial" issued by the National Medical Products Administration for SQ-23101 Injection. The relevant situation is hereby announced as follows:

I. Basic Information of the Drug

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.